Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2025 Earnings Call Transcript March 19, 2026 Eton Pharmaceuticals, Inc. misses on ...

As you have seen, it has been a very active time at Eton. During the call, we will review fourth quarter results, provide ...

Q4 2025 Earnings Call March 19, 2026 4:30 PM EDTCompany ParticipantsDavid Krempa - Chief Business OfficerSean Brynjelsen ...

Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...

This guide explains diabetes insipidus, including common symptoms, hormone causes, diagnosis tests, and medical treatment ...

The FDA approved desmopressin acetate (Desmoda) oral solution for the management of central diabetes insipidus in adults and children, developer Eton Pharmaceuticals announced. The vasopressin analog ...

Pharmacokinetic data from a crossover study demonstrated that the liquid formulation is bioequivalent to an existing FDA-approved oral desmopressin reference product. The Food and Drug Administration ...

Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.

DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing fo ...

Please provide your email address to receive an email when new articles are posted on . Desmoda is the first oral solution approved to manage central diabetes insipidus, according to Eton ...